Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Net Income (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Net Income for 8 consecutive years, with -$13.5 million as the latest value for Q4 2025.

  • Quarterly Net Income rose 37.59% to -$13.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$94.8 million through Dec 2025, down 142.54% year-over-year, with the annual reading at -$64.0 million for FY2025, 15.11% up from the prior year.
  • Net Income for Q4 2025 was -$13.5 million at Outlook Therapeutics, up from -$14.8 million in the prior quarter.
  • The five-year high for Net Income was -$13.5 million in Q4 2025, with the low at -$46.4 million in Q1 2025.